ReviewPituitary2019
Neuroendocrine changes after aneurysmal subarachnoid haemorrhage.
Review in Pituitary, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 28 citations in OpenAlex.
- Metabolic Chaos After Aneurysmal Subarachnoid Haemorrhage: Longitudinal Glucose-Potassium Ratio Dynamics and Clinical Outcomes.Biomedicines · 2026Article
- Dynamic of Cerebrospinal Fluid and Acute-Phase Proteins After Subarachnoid Hemorrhage: The Lumbar Compartment as Blind Spot?Neurocritical care · 2026Article
- The Prognostic Significance of Low-Triiodothyronine Syndrome in Aneurysmal Subarachnoid Hemorrhage.Biomedicines · 2026Article
- Serum peroxiredoxin 2 emerges as a predictive biomarker of poor neurological outcome and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a prospective cohort study.Neurosurgical review · 2025Article
- Value of cerebrovascular hemodynamics and thromboelastogram-related parameters in evaluating the effect of Naomai Jiejing Decoction on the rehabilitation of patients with aneurysmal subarachnoid hemorrhage.African health sciences · 2025Observational
- Morbidities and mortality among hospitalized patients with hypopituitarism: Prevalence, causes and management.Reviews in endocrine & metabolic disorders · 2024Review
- Sheehan syndrome presenting as acute renal failure: A rare case report from Somalia.Annals of medicine and surgery (2012) · 2022Article
- The pathophysiological mechanism between hypopituitarism and nonalcoholic fatty liver disease.iLIVER · 2022Review
- Transcranial Doppler for Early Prediction of Cognitive Impairment after Aneurysmal Subarachnoid Hemorrhage and the Associated Clinical Biomarkers.Stroke research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe prevalence of pituitary dysfunction is high following aneurysmal subarachnoid hemorrhage (aSAH) and when occurs it may contribute to residual symptoms of aSAH such as decreased cognition and quality of life. Hypopituitarism following aSAH may have non-specific, subtle symptoms and potentially serious consequences if remained undiagnosed.
methodsWe reviewed the literature on epidemiology, pathophysiology, diagnostic methods and management of neuroendocrine changes after aSAH as well as on the impact of pituitary dysfunction on outcome of the patient.
resultsThe prevalence rates of pituitary dysfunction after aSAH varies greatly across studies due to different diagnostic methods, though growth hormone deficiency is generally the most frequently reported followed by adrenocorticotropic hormone, gonadotropin and thyroid stimulating hormone deficiencies. Pituitary deficiency tends to improve over time after aSAH but new onset deficiencies in chronic phase may also occur. There are no clinical parameters to predict the presence of hypopituitarism after aSAH. Age of the patient and surgical procedures are risk factors associated with development of hypopituitarism but the effect of pituitary dysfunction on outcome of the patient is not clear. Replacement of hypocortisolemia and hypothyroidism is essential but treatment of other hormonal insufficiencies should be individualized.
conclusionsHypopituitarism following aSAH necessitates screening despite lack of gold standard evaluation tests and cut-off values in the follow up, because missed diagnosis may lead to untoward consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.